Monday November 23 2009 | Biotechnology feed | All feeds
|
|
KAI Pharmaceuticals, Inc.
Download detailed PDF Members: KAI Pharmaceuticals is a biology-based product-driven pharmaceutical company developing a new class of therapeutics targeting cell-signaling enzymes that affect numerous disease pathways. The company is leveraging its leadership position in protein kinase C (PKC), an important and validated family of kinases, to rapidly advance product candidates into human clinical trials.KAI is developing therapeutics that selectively activate or inhibit specific enzymes within the PKC family. These enzymes, or "isozymes", are known to play a fundamental role in the pathophysiology of major diseases including cardiovascular disease, pain, cancer, diabetes and inflammatory diseases. KAI's approach is based on the proprietary discovery that intracellular PKC isozymes can be independently and individually modulated without affecting highly homologous kinases. This unique approach overcomes lack of specificity, the primary deficiency in previous attempts to develop PKC-targeted therapeutics.
This page has been viewed 463 times since April 2007, the link to the organisation's website has been followed 60 times Recent Search Terms used to find this page: kai pharmaceutical | PKC Pharmaceuticals Inc | Kai pharma | Kai pharma | kaiphar | kai pharmaceuticals | kai company list | . Search for more companies in San Francisco Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for KAI Pharmaceuticals, Inc. | ||||||||||||||||||||||||||||||||||||
|